We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer AG (BAYRY - Free Report) reported first-quarter 2021 core earnings of 78 cents per American Depositary Receipt ("ADR"), which beat the Zacks Consensus Estimate of 77 cents and also increased from the year-ago quarter’s earnings of 74 cents per share.
Total sales in the first quarter were $14.86 billion, up from $14.16 billion in the year-ago quarter. Sales also beat the Zacks Consensus Estimate of $14.43 billion.
Shares of Bayer have rallied 9.9% in the year so far, compared with the industry’s increase of 5%.
All growth rates mentioned below are on a year-over-year basis and after adjusting for currency and portfolio changes.
Quarter in Detail
The company started reporting under three segments — Pharmaceuticals, Consumer Health and Crop Science — from the fourth quarter of 2019. Please note that the company had announced divestment of its Animal Health business to Elanco in 2019 and reports the segment under discontinued operations.
In the reported quarter, Crop Science sales were €6.646 billion, up 6.4% from the year-ago quarter driven by strong growth in the Latin America and Asia/Pacific markets. Herbicide sales increased 13.3% as a result of volume gains in all regions and higher prices. Business also improved at Fungicides and Vegetable Seeds. Sales of Corn Seed & Traits remained flat year over year.
Revenues in the Pharmaceuticals segment decreased 0.4% to €4.365 billion in the first quarter. In China, the negative effects from the implementation of new tender procedures for the products, Glucobay and Avelox, were partly offset by growth in other products, especially blood thinner drug, Xarelto, which the company co-developed with J&J (JNJ - Free Report) . Xarelto sales increased 6.5%, mainly as a result of higher volumes. in China and Russia. Sales of the ophthalmology drug, Eylea, increased 15.8%, driven by the launch of its prefilled syringes and strong demand in China. However, growth in Europe continued to be adversely impacted due to COVID-19.
Consumer Health sales were down 4.4% year over year to €1.252 billion in the first quarter primarily due to protective measures introduced in various regions due to the ongoing lockdowns.
2021 Guidance
Bayer reiterated the financial guidance it provided early this year. The company expects to post sales of about €42-€43 billion. The Zacks Consensus Estimate stands at $49.16 billion.
Bayer expects to generate core earnings per share of about €6.10 to €6.30.
ASLAN Pharmaceuticals’ loss per share estimates have narrowed 12.5% for 2021 and 23.3% for 2022 over the past 60 days. The stock has surged 51.9% year to date.
Repligen’s earnings estimates have been revised 15.7% upward for 2021 and 13.4% upward for 2022 over the past 60 days.
Bayer Aktiengesellschaft Price, Consensus and EPS Surprise
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Bayer's (BAYRY) Q1 Earnings & Revenues Surpass Estimates
Bayer AG (BAYRY - Free Report) reported first-quarter 2021 core earnings of 78 cents per American Depositary Receipt ("ADR"), which beat the Zacks Consensus Estimate of 77 cents and also increased from the year-ago quarter’s earnings of 74 cents per share.
Total sales in the first quarter were $14.86 billion, up from $14.16 billion in the year-ago quarter. Sales also beat the Zacks Consensus Estimate of $14.43 billion.
Shares of Bayer have rallied 9.9% in the year so far, compared with the industry’s increase of 5%.
All growth rates mentioned below are on a year-over-year basis and after adjusting for currency and portfolio changes.
Quarter in Detail
The company started reporting under three segments — Pharmaceuticals, Consumer Health and Crop Science — from the fourth quarter of 2019. Please note that the company had announced divestment of its Animal Health business to Elanco in 2019 and reports the segment under discontinued operations.
In the reported quarter, Crop Science sales were €6.646 billion, up 6.4% from the year-ago quarter driven by strong growth in the Latin America and Asia/Pacific markets. Herbicide sales increased 13.3% as a result of volume gains in all regions and higher prices. Business also improved at Fungicides and Vegetable Seeds. Sales of Corn Seed & Traits remained flat year over year.
Revenues in the Pharmaceuticals segment decreased 0.4% to €4.365 billion in the first quarter. In China, the negative effects from the implementation of new tender procedures for the products, Glucobay and Avelox, were partly offset by growth in other products, especially blood thinner drug, Xarelto, which the company co-developed with J&J (JNJ - Free Report) . Xarelto sales increased 6.5%, mainly as a result of higher volumes. in China and Russia. Sales of the ophthalmology drug, Eylea, increased 15.8%, driven by the launch of its prefilled syringes and strong demand in China. However, growth in Europe continued to be adversely impacted due to COVID-19.
Consumer Health sales were down 4.4% year over year to €1.252 billion in the first quarter primarily due to protective measures introduced in various regions due to the ongoing lockdowns.
2021 Guidance
Bayer reiterated the financial guidance it provided early this year. The company expects to post sales of about €42-€43 billion. The Zacks Consensus Estimate stands at $49.16 billion.
Bayer expects to generate core earnings per share of about €6.10 to €6.30.
Zacks Rank & Stocks to Consider
Bayer currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the healthcare sector include ASLAN Pharmaceuticals Limited (ASLN - Free Report) and Repligen Corporation (RGEN - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ASLAN Pharmaceuticals’ loss per share estimates have narrowed 12.5% for 2021 and 23.3% for 2022 over the past 60 days. The stock has surged 51.9% year to date.
Repligen’s earnings estimates have been revised 15.7% upward for 2021 and 13.4% upward for 2022 over the past 60 days.
Bayer Aktiengesellschaft Price, Consensus and EPS Surprise
Bayer Aktiengesellschaft price-consensus-eps-surprise-chart | Bayer Aktiengesellschaft Quote
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
AccessZacks Top 10 Stocks for 2021 today >>